863 Mitten Road
Tel: 650-931-6236 ext 502
About ApexigenApexigen is a biopharmaceutical product development company advancing a pipeline of novel product candidates with the potential to address life-threatening and difficult to treat diseases. The company’s proprietary technology platform enables the discovery and development of superior antibody product candidates that are able to impact previously inaccessible disease mechanisms.
While many companies are working to develop antibody therapies based on mouse- or human-derived antibody technologies, Apexigen is pioneering a movement into therapeutics based on rabbit-derived humanized monoclonal antibodies as a means of providing therapeutic benefits that have not been achieved through the use of other technologies.
Several blockbuster antibody drugs have been developed with existing mouse and human antibody technologies and display libraries. However, the development of the next generation of antibody-based drugs will require capabilities that exceed those of current technologies in order to bind rare or intractable antigen epitopes and to exert novel effects on disease processes. The key to these next generation therapeutics lies in harnessing the inherent advantages of rabbit antibodies, which have been used successfully in research settings for decades. These advantages are the result of rabbit’s ability to generate a much greater diversity of unique high quality antibodies - with high affinity, high specificity and which bind unique antigen epitopes. These attributes enable the discovery of antibodies that are capable of targeting previously unreachable disease mechanisms.
The company’s proprietary platform technology has allowed Apexigen to build a strong and broad pipeline of seven unique humanized monoclonal antibody programs spanning indications including oncology, inflammatory disease and ophthalmology. Of these seven candidates, four are currently the subject of development partnerships with leading life science companies.
Apexigen’s most advanced internal development program, APX005, is a humanized monoclonal antibody targeting the CD40 protein for the treatment of cancers. Apexigen believes that CD40-induced activation of the immune system by APX005 has the potential to treat a variety of difficult to treat cancers, such as pancreatic cancer, and has exhibited potent anti-tumor effects in animal models.
Collaboration is one of Apexigen’s strengths. At present, seven corporate collaborations are in place, representing both product development collaborations and antibody technology collaborations. Through the building of successful collaborations, Apexigen is able to develop a broad base of antibody products and promote wider use of its antibody technology platform.
45 articles with Apexigen
Apexigen Announces First Preclinical Data Presentations On Novel Anti-TNFR2 And Anti-SIRPα Antibody Programs At The 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced two upcoming poster presentations at the 35th Society for Immunotherapy of Cancer Annual Meeting, to be held November 9-14, 2020.
Apexigen's APX005M Granted Orphan Drug Designations for the Treatment of Esophageal and Gastroesophageal Junction Cancer and for the Treatment of Pancreatic Cancer
Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced that the U.S. Food and Drug Administration has granted orphan drug designation status to APX005M for the treatment of esophageal and gastroesophageal junction cancer and for the treatment of pancreatic cancer.
Apexigen, Inc., a clinical-stage biopharmaceutical company, announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview of the company at the upcoming Solebury Trout Fall 2020 Virtual Private Company Showcase.
Apexigen, Inc. announced the appointment of Jakob Dupont, M.D., to its Board of Directors.
Apexigen, Inc. announced the appointment of Gordon Ringold, Ph.D., to its Board of Directors.
Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced that Xiaodong Yang , M.D., Ph.D., President and Chief Executive Officer, plans to present an overview of the company at the upcoming Solebury Trout Virtual Investor Conference. The 25-minute presentation includes an interactive Q&A with participants
Proceeds to Support Clinical Development of Immuno-oncology Therapeutic APX005M and Advancement of New Immunotherapeutic Antibodies into Clinical Evaluation
Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, will present at the following upcoming investor conferences
Apexigen, Inc. announced today the appointments of Jason Wright, Ph.D., as Vice President, CMC and Thomas Jahn, M.D., Ph.D., as Vice President, Clinical Development
Apexigen's CEO, Xiaodong Yang, Recognized Among 100 Most Intriguing Entrepreneurs at Goldman Sachs 2019 Builders + Innovators Summit
Apexigen, Inc. announced today that Goldman Sachs is recognizing its founder and CEO, Xiaodong Yang, as one of the 100 Most Intriguing Entrepreneurs of 2019 at its Builders + Innovators Summit in Santa Barbara, California.
Apexigen, Inc. announced today that Xiaodong Yang, M.D., Ph.D., President & Chief Executive Officer, will present at the upcoming Solebury Trout Private Company Showcase at the offices of Davis Polk & Wardwell, LLP in New York on Friday, October 18, 2019 at 11:40am EDT.
Apexigen, Inc. announced that Herb C. Cross has joined its Board of Directors as an independent director.
Apexigen, Inc. announced its participation at the following upcoming oncology-focused conferences to discuss the role of the CD40 pathway in next-generation cancer immunotherapy and Apexigen's lead product candidate APX005M, a monoclonal antibody targeting CD40.
Former President and COO of Celgene appointed independent director
Apexigen Presents Clinical Data On CD40 Antibody APX005M In Metastatic Melanoma At The AACR Annual Meeting 2019
Apexigen, Inc., a clinical-stage biopharmaceutical company, today presented new clinical data on APX005M at the American Association for Cancer Research (AACR) Annual Meeting, taking place March 29 - April 3, 2019 in Atlanta, GA.
Apexigen Announces New Clinical Data On APX005M In Combination Therapy For Pancreatic Cancer At The AACR Annual Meeting 2019
APX005M in Combination Therapy was Well Tolerated and Induced Tumor Shrinkage in 20 of 24 Patients with Metastatic Pancreatic Cancer, Several Patients on Therapy for Over a Year
Apexigen Announces Clinical Data Presentations On CD40 Antibody APX005M At The AACR Annual Meeting 2019
Apexigen, Inc. announced new clinical data on APX005M will be presented at the American Association for Cancer Research Annual Meeting, to be held March 29 – April 3, 2019 in Atlanta, GA.
Apexigen, Inc. announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, will present at the following upcoming investor conferences
Apexigen today announced a collaboration with Columbia University Irving Medical Center on a new Phase 2 study for its lead immuno-oncology (I-O) therapeutic APX005M, a monoclonal antibody targeting CD40, in combination with doxorubicin and olaratumab in patients with advanced sarcomas.
Apexigen, Inc. today announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, will present at Piper Jaffray's 30th Annual Healthcare Conference on Tuesday, November 27, 2018 at 3:30 PM ET in New York, NY.